Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The annualized rate of severe asthma exacerbations was 0.46 (95% confidence interval [CI], 0.39 to 0.53) among patients assigned to 200 mg of dupilumab every 2 weeks and 0.87 (95% CI, 0.72 to 1.05 ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Dupilumab significantly improved asthma control and quality of life among children aged 6 to 11 years with uncontrolled moderate to severe asthma, researchers reported at the virtual European ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Source Reference: Lugogo NL, et al "Characterization of patients with asthma treated with dupilumab in a real-world setting: The RAPID registry" CHEST 2022; DOI: 10.1016/j.chest.2022.08.2185.

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the ...

Better asthma control, as indicated by lower mean scores on the Asthma Control Questionnaire-5, were seen in both the dupilumab and placebo groups. SEATTLE — Asthma control, as measured by the 5 ...

The new study was funded by Sanofi and Regeneron Pharmaceuticals, which make dupilumab. Asthma is the most common chronic disorder of childhood and affects more than 5 million children younger ...

Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with ...

Dupixent ® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial Data ...